Jean-Pierre Delord

Jean-Pierre Delord

UNVERIFIED PROFILE

Are you Jean-Pierre Delord?   Register this Author

Register author
Jean-Pierre Delord

Jean-Pierre Delord

Publications by authors named "Jean-Pierre Delord"

Are you Jean-Pierre Delord?   Register this Author

100Publications

3874Reads

44Profile Views

Definitive radiochemotherapy or initial surgery for oropharyngeal cancer : To what extent can p16 expression be used in the decision process?

Strahlenther Onkol 2019 Jun 15;195(6):496-503. Epub 2019 Mar 15.

Radiation Oncology Department, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, 1 avenue Irène Joliot-Curie, Cedex 9, 31059, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00066-019-01451-8DOI Listing
June 2019

Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors.

Invest New Drugs 2018 12 29;36(6):1044-1059. Epub 2018 May 29.

Institut Universitaire du Cancer de Toulouse-Oncopole and Institut Claudius Regaud, 1 avenue Irène Joliot-Curie, 31059, Toulouse Cedex 9, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-018-0601-1DOI Listing
December 2018

Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer.

Cancer Chemother Pharmacol 2018 12 22;82(6):979-986. Epub 2018 Oct 22.

Institut Universitaire du Cancer de Toulouse, Oncopôle, 1 avenue Irène Joliot-Curie, 31059, Toulouse Cedex 9, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-018-3689-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267664PMC
December 2018

Addressing heterogeneity in the design of phase II clinical trials in geriatric oncology.

Eur J Cancer 2018 11 14;103:120-126. Epub 2018 Sep 14.

Biostatistics Unit, Institut Claudius Regaud-IUCT-O, Toulouse, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.07.136DOI Listing
November 2018

Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.

J Clin Oncol 2018 10 7;36(30):3007-3014. Epub 2018 May 7.

Jeremy Lewin and Lillian L. Siu, Princess Margaret Cancer Center, Toronto, Ontario, Canada; Jean-Charles Soria and Christophe Massard, Institut Gustave Roussy and University Paris-Sud, Villejuif; Jean-Pierre Delord, Institut Claudius Regaud Oncopole, Toulouse; Mohamed Bekradda, Oncology Therapeutic Development, Clichy; Keyvan Rezai, Hôpital René Huguenin, Saint-Cloud, France; Anastasios Stathis, Oncology Institute of Southern Switzerland, Bellinzona; Solange Peters, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Ahmad Awada and Philippe G. Aftimos, Université Libre de Bruxelles, Brussels, Belgium; and Zhen Zeng, Azher Hussain, and Susan Perez, Merck & Co, Kenilworth, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.2292DOI Listing
October 2018

[WHO classification of head and neck tumours 2017: Main novelties and update of diagnostic methods].

Bull Cancer 2018 Jun;105(6):596-602

IUCT-Oncopole, département d'oncologie médicale et de recherche clinique, 31000 Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2018.04.004DOI Listing
June 2018

Effect of combined inhibition of p110 alpha PI3K isoform and STAT3 pathway in ovarian cancer platinum-based resistance.

Oncotarget 2018 Jun 5;9(43):27220-27232. Epub 2018 Jun 5.

Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR 1037 INSERM, University Toulouse III, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.25513DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007481PMC
June 2018

Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Non-Small-cell Lung Cancer: A Phase I Study.

Clin Lung Cancer 2018 05 21;19(3):e277-e285. Epub 2017 Nov 21.

Department of Radiation Oncology, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse, Oncopole, Toulouse, France; Université Paul Sabatier, Toulouse, France; INSERM U1037, Centre de Recherche Contre le Cancer de Toulouse, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2017.11.002DOI Listing
May 2018

Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2.

Br J Cancer 2018 02 16;118(3):344-352. Epub 2018 Jan 16.

Department of Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer-Oncopole, Toulouse 31100, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2017.436DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808039PMC
February 2018

Comparison of variable selection methods for high-dimensional survival data with competing events.

Comput Biol Med 2017 12 20;91:159-167. Epub 2017 Oct 20.

Department of Biostatistics, Institut Claudius Regaud, IUCT-O, Toulouse, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.compbiomed.2017.10.021DOI Listing
December 2017

Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination.

Melanoma Res 2017 10;27(5):485-491

Departments of aRadiation OncologybBiostatistics, Claudius Regaud InstitutecDepartment of Medical OncologydDepartment of Dermatology, Toulouse University Hospital, Larrey Hospital, The Toulouse University Institute of Cancer, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000386DOI Listing
October 2017

[Observational study of outpatient unit duration of stay depending on the route of administration (intravenous vs subcutaneous) for a targeted therapy].

Bull Cancer 2017 Oct 13;104(10):869-874. Epub 2017 Oct 13.

Institut universitaire du cancer Toulouse-Oncopôle, 1, avenue Irène-Joliot-Curie, 31059 Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2017.08.007DOI Listing
October 2017

Severe Onycholysis and Eyelash Trichomegaly Following Use of New Selective Pan-FGFR Inhibitors.

JAMA Dermatol 2017 07;153(7):723-725

Departments of Oncodermatology and Clinical Research, Institut Claudius Regaud, Institut Universitaire du Cancer, Toulouse Oncopole, France.

View Article

Download full-text PDF

Source
http://archderm.jamanetwork.com/article.aspx?doi=10.1001/jam
Publisher Site
http://dx.doi.org/10.1001/jamadermatol.2017.0500DOI Listing
July 2017

[Subgroup analysis and forest plots: Limitations and interests].

Bull Cancer 2017 Jan 4;104(1):92-100. Epub 2016 Nov 4.

Institut Claudius-Regaud, IUCT-oncopole, bureau des essais cliniques, 1, avenue Irène-Joliot-Curie, 31059 Toulouse, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2016.09.023DOI Listing
January 2017

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.

J Clin Oncol 2017 Jan 21;35(2):157-165. Epub 2016 Nov 21.

Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d'Oncologia, Barcelona; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy, Villejuif; Jean-Pierre Delord, Institute Universitaire du Cancer de Toulouse, Toulouse; Philippe A. Cassier, Centre Regional Leon-Berard, Lyon; Mario Campone, Institute de Cancerologie de l'Ouest-René Gauducheau, Nantes, France; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, and Utrecht University, Utrecht, the Netherlands; D. Ross Camidge, University of Colorado, Aurora, CO; Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Howard Burris, Sarah Cannon Research Institute, Nashville; G. Gary Tian, The West Clinic, Memphis, TN; Zev A. Wainberg, UCLA School of Medicine, Los Angeles, CA; Wan-Teck Lim, National Cancer Centre, Singapore; Patricia LoRusso, Yale Cancer Center, New Haven, CT; Katie Parker, Xueying Chen, Somesh Choudhury, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dale Porter, Novartis Institutes for Biomedical Research, Cambridge, MA; Francois Ringeisen, Novartis Pharma AG; and Diana Graus-Porta, Novartis Institutes for Biomedical Research, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.2048DOI Listing
January 2017

Development of Photoonycholysis with Vandetanib Therapy.

Skin Appendage Disord 2017 Jan 3;2(3-4):146-151. Epub 2016 Nov 3.

Department of Oncodermatology, Institut Claudius Regaud, Institut Universitaire du Cancer, Toulouse Oncopole, Toulouse, France; Department of Medical Oncology and Clinical Research, Institut Claudius Regaud, Institut Universitaire du Cancer, Toulouse Oncopole, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000452425DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264363PMC
January 2017

[The role of the bed manager nurse in medical oncology].

Soins 2016 Oct;61(809):18-21

Institut universitaire du cancer, Oncopole, Institut Claudius-Regaud, 1, avenue Irène-Joliot-Curie, 31000 Toulouse, France.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00380814163014
Publisher Site
http://dx.doi.org/10.1016/j.soin.2016.08.002DOI Listing
October 2016

Characteristics and Clinical Outcomes of Sarcomatoid Carcinoma of the Lung.

Clin Lung Cancer 2016 09 17;17(5):391-397. Epub 2016 Mar 17.

Pulmonary Medicine Unit, Hôpital Larrey, Centre Hospitalier Universitaire Toulouse, Université de Toulouse III, Toulouse, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2016.03.001DOI Listing
September 2016

Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies.

Curr Opin Oncol 2016 07;28(4):254-63

aDepartment of Medical Oncology and Clinical Research bDepartment of Oncodermatology cDepartment of Pathology dDepartment of Oral Medicine, Institut Claudius Regaud, Institut Universitaire du Cancer, Toulouse Oncopole eDepartment of Oncopneumology, Hopital Larrey, Toulouse University, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000290DOI Listing
July 2016

Primary care physicians and oncologists are partners in cancer announcement.

Support Care Cancer 2016 06 14;24(6):2473-9. Epub 2015 Dec 14.

Inserm U1027, Faculty of Medicine, 37 allées Jules Guesde, 31073, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-015-3049-2DOI Listing
June 2016

Guideline sheets on the side effects of anticancer drugs are useful for general practitioners.

Support Care Cancer 2015 Dec 27;23(12):3473-80. Epub 2015 Mar 27.

Faculté de Médecine, UMR 1027 INSERM-UPS, 37 Allées Jules Guesde, 31000, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-015-2705-xDOI Listing
December 2015

Acute skin reaction suggestive of pembrolizumab-induced radiosensitization.

Melanoma Res 2015 Dec;25(6):555-8

Departments of aDermatology bRadiation Oncology cPathology dClinical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer, Toulouse Oncopole, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000191DOI Listing
December 2015

[Nurse telephone support at home during chemotherapy].

Rev Infirm 2015 Aug-Sep(213):37-9

Institut Claudius Regaud, Institut universitaire du cancer de Toulouse Oncopole, 1, avenue Irène Joliot-Curie, 31059 Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.revinf.2015.06.011DOI Listing
December 2015

Evaluation of the effects of hyaluronic acid-carboxymethyl cellulose barrier on ovarian tumor progression.

J Ovarian Res 2014 16;7:40. Epub 2014 Apr 16.

EA4553, Institut Claudius Regaud, 20-24 rue du pont St Pierre, 31052 Toulouse, France ; Surgery Department, Institut Claudius Regaud, 20-24 rue du pont St Pierre, 31052 Toulouse, France.

View Article

Download full-text PDF

Source
http://ovarianresearch.biomedcentral.com/articles/10.1186/17
Publisher Site
http://dx.doi.org/10.1186/1757-2215-7-40DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3996858PMC
October 2015

Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death.

Int J Mol Sci 2012 30;13(8):9545-71. Epub 2012 Jul 30.

EA4553, Institut Claudius Regaud, F-31062 Toulouse, France and University of Toulouse III, Toulouse F-31052, France; E-Mails: (M.C.); (B.T.); (J.-P.D.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms13089545DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3431813PMC
August 2015

CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients.

Clin Cancer Res 2015 Jun 11;21(12):2753-62. Epub 2015 Mar 11.

Roche Innovation Center Penzberg, Oncology Division, Roche Pharmaceutical Research and Early Development, Penzberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2141DOI Listing
June 2015

Intensity-modulated radiotherapy for laryngeal and hypopharyngeal cancer: minimization of late dysphagia without jeopardizing tumor control.

Strahlenther Onkol 2015 Mar 1;191(3):225-33. Epub 2014 Nov 1.

Department of Radiation Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer, 1 avenue Irène Joliot-Curie, 31059, Toulouse, Cedex 9, France,

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00066-014-0767-1
Publisher Site
http://dx.doi.org/10.1007/s00066-014-0767-1DOI Listing
March 2015

[Cetuximab cutaneous adverse drug reactions: a marker of efficacy for metastatic colorectal cancer and head-neck cancer?].

Therapie 2014 Nov-Dec;69(6):499-507. Epub 2014 Oct 1.

Service de pharmacologie médicale et clinique, Centre Midi-Pyrénées de pharmacovigilance, de pharmacoépidémiologie et d'informations sur le médicament, Centre hospitalier universitaire de Toulouse, Toulouse, France - Laboratoire de pharmacologie médicale et clinique, Faculté de médecine de l'université de Toulouse III Paul Sabatier, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2515/therapie/2014060DOI Listing
February 2015

Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series.

Breast Cancer Res Treat 2014 Jul 15;146(2):451-6. Epub 2014 Jun 15.

Department of dermatology, Institut Claudius Regaud, Institut Universitaire Cancer Toulouse-oncopole, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-014-3001-zDOI Listing
July 2014

Emerging new anticancer therapies in 2013.

Curr Opin Oncol 2014 May;26(3):357-62

Departement of Medical Oncology, Institut Claudius Regaud, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000081DOI Listing
May 2014

Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition.

Cancer Metastasis Rev 2014 Mar;33(1):17-39

EA4553, Institut Claudius Regaud, 31062, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10555-013-9456-2DOI Listing
March 2014

Cystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatment.

Springerplus 2013 18;2:679. Epub 2013 Dec 18.

Department of Medical Oncology, Institute Claudius Regaud, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/2193-1801-2-679DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872282PMC
January 2014

Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck.

Invest New Drugs 2013 Oct 10;31(5):1207-16. Epub 2013 Feb 10.

Service d'Oncologie Médicale, Centre du Cancer, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (IREC, MIRO), Université Catholique de Louvain, Bruxelles, Belgium,

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s10637-013-9933
Web Search
http://link.springer.com/10.1007/s10637-013-9933-z
Publisher Site
http://dx.doi.org/10.1007/s10637-013-9933-zDOI Listing
October 2013

Drugs and cancer: an analysis of the French Pharmacovigilance Database.

Therapie 2013 May-Jun;68(3):149-54. Epub 2013 Jul 26.

Hôpitaux Universitaires de Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2515/therapie/2013023DOI Listing
September 2013

A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors.

Invest New Drugs 2013 Aug 11;31(4):900-9. Epub 2012 Nov 11.

Clinical Research Unit, Medical Oncology Department, Comprehensive Cancer Center Eugène Marquis, CS 44229, 35042 Rennes Cedex, France.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-012-9893-8
Publisher Site
http://dx.doi.org/10.1007/s10637-012-9893-8DOI Listing
August 2013

Gene expression profiling on pre- and post-erlotinib tumors from patients with head and neck squamous cell carcinoma.

Head Neck 2013 Jun 13;35(6):809-18. Epub 2012 Jul 13.

EA4553 and Université de Toulouse, 20-24 Rue du Pont St Pierre, 31052 Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hed.23036DOI Listing
June 2013

[The management of the metastatic disease by the surgeons].

Bull Cancer 2013 Apr;100(4):357-62

Faculté Toulouse-III, Institut Claudius-Regaud, 20-24 rue du Pont-Saint-Pierre, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/bdc.2013.1730DOI Listing
April 2013

Peritoneal pseudomyxoma arising from the urachus.

Surg Oncol 2012 Mar 26;21(1):1-5. Epub 2010 Feb 26.

Institut Claudius Regaud, Surgery, 20-24, Rue du Pont Saint Pierre, 31052 Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.suronc.2009.12.004DOI Listing
March 2012

Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study.

Anticancer Res 2011 Jan;31(1):359-66

Université de Lyon and Department of Medical Oncology, Centre Hospitalier Lyon Sud, Pierre-Bénite, France.

View Article

Download full-text PDF

Source
January 2011

Development of a new radioligand for cholecystokinin receptor subtype 2 scintigraphy: from molecular modeling to in vivo evaluation.

Bioorg Med Chem 2010 Jul 19;18(14):5400-12. Epub 2010 May 19.

INSERM 563, Equipe Marc Poirot, CPTP, Département d'Imagerie Médicale, Institut Claudius Regaud, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmc.2010.05.031DOI Listing
July 2010

[Nursing research on using acupressure wrist bands in oncology].

Rev Infirm 2010 Jun(161):39-40

Centre de lutte contre le cancer Claudius Regaud, Toulouse.

View Article

Download full-text PDF

Source
June 2010

Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma.

Eur J Cancer 2009 Sep 10;45(13):2316-23. Epub 2009 Jun 10.

EA3035 and Université de Toulouse, Laboratoire de Pharmacologie Clinique et Expérimentale des Médicaments Anticancéreux, 20-24, F-31052 Toulouse, Cedex, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2009.05.007DOI Listing
September 2009

Combination chemotherapy of vinorelbine and cisplatin: a phase I pharmacokinetic study in patients with metastatic solid tumors.

Anticancer Res 2009 Feb;29(2):553-60

Institut Claudius Regaud, Toulouse, France.

View Article

Download full-text PDF

Source
February 2009

Vinflunine: a new microtubule inhibitor agent.

Clin Cancer Res 2008 Mar;14(6):1625-32

Centre René Gauducheau, Saint-Herblain, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-2219DOI Listing
March 2008

Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma.

Clin Cancer Res 2007 Dec;13(23):7086-92

Laboratoire de Pharmacologie Clinique et Expérimentale des Médicaments Anticancéreux, EA3035, Institut Claudius Regaud, Université Paul Sabatier, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-1370DOI Listing
December 2007

Phase-I study of a new schedule based on increasing days of topotecan administration associated with dose individualisation.

Cancer Chemother Pharmacol 2006 Aug 22;58(2):189-94. Epub 2005 Nov 22.

Institut Claudius-Regaud, Université Paul-Sabatier, EA3035 Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-005-0142-0DOI Listing
August 2006

Vinflunine: a novel antitubulin agent in solid malignancies.

Expert Opin Investig Drugs 2005 Oct;14(10):1259-67

Centre René Gauducheau, Saint-Herblain, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.14.10.1259DOI Listing
October 2005

Serum cystatin C is a better marker of topotecan clearance than serum creatinine.

Clin Cancer Res 2005 Apr;11(8):3038-44

EA 3035 and Department of Clinical Biology, Institut Claudius-Regaud, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-04-2086DOI Listing
April 2005